论文部分内容阅读
目的：观察重组人白介素-11( IL-11)在防治鼻咽癌放射治疗相关性口腔粘膜炎的疗效。方法选取2013年3月～2014年12月在我院肿瘤科就诊的鼻咽癌患者58例，随机分为重组人白介素-11组（n=30）及生理盐水组(n=28)，从放疗第一天开始至放疗，当两组患者出现II级及以上口腔粘膜炎时予常规对症处理。观察两组黏膜炎发生率，发生时间，反应程度及不了反应等。结果1.重组人白介素-11组和对照组I级与III级粘膜炎发生率分别为46.7%和3.60%，16.7%和42.8%(P<0.05)；2.在照射剂量达20Gy及30Gy时，白介素-11组口腔粘膜炎发生率分别为33.3%和63.4%，而对照组分别为78.5%和21.5%(P<0.05)；3.白介素-11组出现粘膜炎的时间是中位18天，对照组是中位11天( P<0.05)；4.重组人白介素-11和对照组I I I级粘膜炎平均持续时间分别为8.2天和11.4天(P<0.05)。结论重组人白介素-11含漱对防治鼻咽癌放射性口腔粘膜炎有较好的效果，明显推迟口腔粘膜反应出现时间，缩短粘膜修复时间，粘膜反应程度多为Ⅰ级，值得临床推广。“,”Objective To observe the efficacy of recombinant human interleukin-11 ( IL-11) in treatment of oral mucositis related with nasopharyngeal carcinoma(NPC) radiotherapy.Methods 58 cases (from Mar 2013 to Dec 2014) with NPC were randomly divided into the observation group (recombinant human interleukin -11 group n = 30) and the control group (nomal saline group n = 28) . The patients were given conventional treatment if oral mucositis grade were II –IV.Results 1.The incidences of grade I were 46.7% , 3.60% and the incidences of grade III were 16.7%, 42.8% in the observation group and control group respectively(P < 0. 05) .2. in the observation group, the rate of radioactive mucositis at 20Gy and 30Gy was 33.3% and 63.4% respectively, which in the control group was 78.5% and 21.5% respectively(P < 0. 05). 3. The median time of occurrence on radiation mucositis in the observation group and in the control group was 18 and 11days respectively (P < 0. 05). 4. The mean time for radioactive oral mucositis of grade III lasting in the observation group and in the control group was 8.2 and 11.4 days respectively(P < 0. 05).Conclusions Compound recombinant human interleukin-11 solution is effective to prevent and treat the radiotherapy - induced oral mucositis reaction. It has no side effects. So it is valuable for clinical application.